• 1
    Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL. Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990; 322: 8106.
  • 2
    Spitzer TR, Bryson JC, Cirenza E, et al. Randomized double-blind, placebo-controlled evaluation of oral ondansetron in the prevention of nausea and vomiting associated with fractionated total-body irradiation. J Clin Oncol 1994; 12: 24328.
  • 3
    Gregory RE & Ettinger DS. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy. Drugs 1998; 55: 17389.
  • 4
    Simpson K, Spencer CM, McClellan KJ. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 2000; 59: 1297315.
  • 5
    Wilde MI & Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 1996; 52: 77394.
  • 6
    Read NW & Gwee KA. The importance of 5-hydroxytryptamine receptors in the gut. Pharmacol Ther 1994; 62: 15973.
  • 7
    Gershon MD. Review article: roles played by 5-hydroxytryptamine in the physiology of the bowel. Aliment Pharmacol Ther 1999; 13 (Suppl. 2): 1530.
  • 8
    Johnson LR, ed. Physiology of the Gastrointestinal Tract, 3rd edn. New York: Raven Press, 1994.
  • 9
    Buchheit KH, Costall B, Engel G, Gunning SJ, Naylor RJ, Richardson BP. 5-Hydroxytryptamine receptor antagonism by metoclopramide and ICS 205-930 in the guinea-pig leads to enhancement of contractions of stomach muscle strips induced by electrical field stimulation and facilitation of gastric emptying in-vivo. J Pharm Pharmacol 1985; 37: 6647.
  • 10
    Costall B, Gunning SJ, Naylor RJ, Tyers MB. The effect of GR38032F, novel 5-HT3-receptor antagonist, on gastric emptying in the guinea-pig. Br J Pharmacol 1987; 91: 2634.
  • 11
    Miyata K, Yamano M, Kamato T, Akuzawa S. Effect of serotonin (5-HT)3-receptor antagonists YM060, YM114 (KAE-393), ondansetron and granisetron on 5-HT4 receptors and gastric emptying in rodents. Jpn J Pharmacol 1995; 69: 20514.
  • 12
    Haga K, Asano K, Inaba K, Morimoto Y, Setoguchi M. Effect of Y-25130, a selective 5-hydroxytryptamine3 receptor antagonist, on gastric emptying in mice. Arch Int Pharmacodyn Ther 1994; 328: 34455.
  • 13
    Ito C, Isobe Y, Tsuchida K, Higuchi S. 5-Hydroxytryptamine3 receptor and regulation of gastric emptying in rats. Arch Int Pharmacodyn Ther 1996; 331: 20318.
  • 14
    McCallum RW, Mittal RK, Sluss J. Effect of ICS 205-125, a potential prokinetic agent, on upper gastrointestinal (GI) motility in normal subjects. Gastroenterology 1989; 96: A332A332(Abstract).
  • 15
    Akkermans LM, Vos A, Hoekstra A, Roelofs JM, Horowitz M. Effect of ICS 205-930 (a specific 5-HT3 receptor antagonist) on gastric emptying of a solid meal in normal subjects. Gut 1988; 29: 124952.
  • 16
    Stacher G, Bergmann H, Granser-Vacariu GV, et al. Lack of systematic effects of the 5-hydroxytryptamine 3 receptor antagonist ICS 205-930 on gastric emptying and antral motor activity in patients with primary anorexia nervosa. Br J Clin Pharmacol 1991; 32: 6859.
  • 17
    Nielsen OH, Hvid-Jacobsen K, Lund P, Langoholz E. Gastric emptying and subjective symptoms of nausea: lack of effects of a 5-hydroxytryptamine-3 antagonist ondansetron on gastric emptying in patients with gastric stasis syndrome (published erratum appears in Digestion 1990; 47 (4): 235). Digestion 1990; 46: 8996.
  • 18
    Talley NJ, Phillips SF, Haddad A, et al. Effect of selective 5HT3 antagonist (GR 38032F) on small intestinal transit and release of gastrointestinal peptides. Dig Dis Sci 1989; 34: 15115.
  • 19
    Gore S, Gilmore IT, Haigh CG, Brownless SM, Stockdale H, Morris AI. Colonic transit in man is slowed by ondansetron (GR38032F), a selective 5-hydroxytryptamine receptor (type 3) antagonist. Aliment Pharmacol Ther 1990; 4: 13944.
  • 20
    Van Wyk M, Sommers DK, Snyman JR, Moncrieff J. The effect of metoclopramide, ondansetron, and granisetron on liquid gastric emptying in normal subjects. Curr Ther Res 1995; 56: 5816.
  • 21
    Stacher G, Bergmann H, Schneider C, et al. Effects of the 5-HT3 receptor antagonist ICS 205-930 on fat-delayed gastric emptying and antral motor activity. Br J Clin Pharmacol 1990; 30: 418.
  • 22
    Parkman HP, Urbain JL, Knight LC, et al. Effect of gastric acid suppressants on human gastric motility. Gut 1998; 42: 24350.
  • 23
    Chen JZ & McCallum RW. Electrogastrography: Principles and Applications. New York: Raven Press, 1994.
  • 24
    Goo RH, Moore JG, Greenberg E, Alazraki NP. Circadian variation in gastric emptying of meals in humans. Gastroenterology 1987; 93: 5158.
  • 25
    Datz FL. Considerations for accurately measuring gastric emptying. J Nucl Med 1991; 32: 8814.
  • 26
    Ford PV, Kennedy RL, Vogel JM. Comparison of left anterior oblique, anterior and geometric mean methods for determining gastric emptying times. J Nucl Med 1992; 33: 12730.
  • 27
    Phillips WT, McMahan CA, Lasher JC, Blumhardt MR, Schwartz JG. Anterior, posterior, left anterior oblique, and geometric mean views in gastric emptying studies using a glucose solution. Eur J Nucl Med 1995; 22: 1547.
  • 28
    Pfaffenbach B, Adamek RJ, Kuhn K, Wegener M. Electrogastrography in healthy subjects. Evaluation of normal values, influence of age and gender. Dig Dis Sci 1995; 40: 144550.
  • 29
    Parkman HP, Harris AD, Miller MA, Fisher RS. Influence of age, gender, and menstrual cycle on the normal electrogastrogram. Am J Gastroenterol 1996; 91: 12733.
  • 30
    Levanon D, Zhang M, Chen JD. Efficiency and efficacy of the electrogastrogram. Dig Dis Sci 1998; 43: 102330.
  • 31
    Verhagen MA, Luijk HD, Samsom M, Smout AJ. Effect of meal temperature on the frequency of gastric myoelectrical activity. Neurogastroenterol Motil 1998; 10: 17581.
  • 32
    Verhagen MA, Van Schelven LJ, Samsom M, Smout AJ. Pitfalls in the analysis of electrogastrographic recordings. Gastroenterology 1999; 117: 45360.
  • 33
    Witzel L, Heitz PU, Halter F, et al. Effects of prolonged administration of metiamide on serum gastrin, gastrin content of the antrum and gastric corpus, and G-cell population in the rat. Gastroenterology 1979; 76: 9459.
  • 34
    Meyer FD, Gyr K, Hacki WH, et al. The release of pancreatic polypeptide by CCK-octapeptide and some analogues in the dog. Gastroenterology 1981; 80: 7427.
  • 35
    Hettmansperger TP. Statistical Inference Based on Ranks. New York: Wiley, 1984.
  • 36
    Yoshida N & Ito T. Mosapride citrate (AS-4370), a new gastroprokinetic agent, is a partial 5-HT4 receptor agonist in the gut. Neurogastroenterol Motil 1994; 6: 197204.
  • 37
    Haga K, Inaba K, Shoji H, Morimoto Y, Fukuda T, Setoguchi M. The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. Jpn J Pharmacol 1993; 63: 37783.
  • 38
    Rizzi CA, Sagrada A, Schiavone A, et al. Gastroprokinetic properties of the benzimidazolone derivative BIMU 1, an agonist at 5-hydroxytryptamine4 and antagonist at 5-hydroxytryptamine3 receptors. Naunyn Schmiedebergs Arch Pharmacol 1994; 349: 33845.
  • 39
    Kilpatrick GJ & Tyers MB. Inter-species variants of the 5-HT3 receptor. Biochem Soc Trans 1992; 20: 11821.
  • 40
    Nagakura Y, Ito H, Kamato T, Nishida A, Miyata K. Effect of a selective 5-HT3 receptor agonist on gastric motility in fasted and fed dogs. Eur J Pharmacol 1997; 327: 18993.
  • 41
    Mawe GM, Branchek TA, Gershon MD. Blockade of 5-HT-mediated enteric slow EPSPs by BRL 24924: gastrokinetic effects. Am J Physiol 1989; 257: G38696.
  • 42
    Forster ER & Dockray GJ. The effect of ondansetron on gastric emptying in the conscious rat. Eur J Pharmacol 1990; 191: 2358.
  • 43
    Lasheras B, Berjon A, Montanes R, et al. Pharmacological properties of quinoxaline derivatives as a new class of 5-HT3 receptor antagonists. Arzneimittelforschung 1996; 46: 4016.
  • 44
    Gullikson GW, Loeffler RF, Virina MA. Relationship of serotonin-3 receptor antagonist activity to gastric emptying and motor-stimulating actions of prokinetic drugs in dogs. J Pharmacol Exp Ther 1991; 258: 10310.
  • 45
    Roila F, Ballatori E, Tonato M, Del Favero A. 5-HT3 receptor antagonists: differences and similarities. Eur J Cancer 1997; 33: 136470.
  • 46
    Dumuis A, Sebben M, Bockaert J. The gastrointestinal prokinetic benzamide derivatives are agonists at the non-classical 5-HT receptor (5-HT4) positively coupled to adenylate cyclase in neurons. Naunyn Schmiedebergs Arch Pharmacol 1989; 340: 40310.
  • 47
    Kilbinger H, Gebauer A, Haas J, Ladinsky H, Rizzi CA. Benzimidazolones and renzapride facilitate acetylcholine release from guinea-pig myenteric plexus via 5-HT4 receptors. Naunyn Schmiedebergs Arch Pharmacol 1995; 351: 22936.
  • 48
    Linnik MD, Butler BT, Gaddis RR, Ahmed NK. Analysis of serotonergic mechanisms underlying benzamide-induced gastroprokinesis. J Pharmacol Exp Ther 1991; 259: 5017.
  • 49
    Yamano M, Kamato T, Miyata K. Participation of a cholinergic mechanism in 5-hydroxytryptamine (5-HT)3 and 5-HT4 receptor-mediated stimulation of gastric emptying in rats. Arzneimittelforschung 1997; 47: 12426.
  • 50
    Staniforth DH. Oro-caecal transit time in man unaffected by 5-HT3 antagonism. Br J Clin Pharmacol 1989; 27: 701P2P(Abstract).
  • 51
    Thumshirn M, Coulie B, Camilleri M, Zinsmeister AR, Burton DD, Van Dyke C. Effects of alosetron on gastrointestinal transit time and rectal sensation in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2000; 14: 86978.DOI: 10.1046/j.1365-2036.2000.00786.x
  • 52
    Stacher G, Kiss A, Wiesnagrotzki S, Bergmann H, Hobart J, Schneider C. Oesophageal and gastric motility disorders in patients categorised as having primary anorexia nervosa. Gut 1986; 27: 11206.
  • 53
    Feinle C & Read NW. Ondansetron reduces nausea induced by gastroduodenal stimulation without changing gastric motility. Am J Physiol 1996; 271: G5917.
  • 54
    Talley NJ, Phillips SF, Haddad A, et al. GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man. Dig Dis Sci 1990; 35: 47780.
  • 55
    Cohen ML, Bloomquist W, Gidda JS, Lacefield W. Comparison of the 5-HT3 receptor antagonist properties of ICS 205-930, GR38032F and zacopride. J Pharmacol Exp Ther 1989; 248: 197201.
  • 56
    Datz FL, Christian PE, Moore J. Gender-related differences in gastric emptying. J Nucl Med 1987; 28: 12047.
  • 57
    Parkman HP, Miller MA, Trate D, et al. Electrogastrography and gastric emptying scintigraphy are complementary for assessment of dyspepsia. J Clin Gastroenterol 1997; 24: 2149.DOI: 10.1097/00004836-199706000-00006
  • 58
    Besherdas K, Leahy A, Mason I, Harbord M, Epstein O. The effect of cisapride on dyspepsia symptoms and the electrogastrogram in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1998; 12: 7559.
  • 59
    Cheng W, Chan GC, Tam PK. Cytotoxic chemotherapy has minimal direct effect on gastric myoelectric activity in children with 5HT(3) antagonist prophylaxis. Med Pediatr Oncol 2000; 34: 4213.DOI: 10.1002/(sici)1096-911x(200006)34:6<421::aid-mpo7>;2-6
  • 60
    Ladabaum U, Koshy SS, Woods ML, Hooper FG, Owyang C, Hasler WL. Differential symptomatic and electrogastrographic effects of distal and proximal human gastric distension. Am J Physiol 1998; 275: G41824.
  • 61
    Yamada T. Gut hormone release induced by food ingestion. Am J Clin Nutr 1985; 42: 10339.
  • 62
    Schwizer W, Borovicka J, Kunz P, et al. Role of cholecystokinin in the regulation of liquid gastric emptying and gastric motility in humans: studies with the CCK antagonist loxiglumide. Gut 1997; 41: 5004.
  • 63
    Wilmer A, Tack J, Coremans G, Janssens J, Peeters T, Vantrappen G. 5-Hydroxytryptamine-3 receptors are involved in the initiation of gastric phase-3 motor activity in humans. Gastroenterology 1993; 105: 77380.